FMP
TCR2 Therapeutics Inc.
TCRR
NASDAQ
Inactive Equity
TCR2 Therapeutics Inc., a clinical-stage immunotherapy company, focuses on developing novel T cell receptor (TCR) therapies for patients suffering from cancer. The company's lead product candidates include gavo-cel, a mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors, which is in phase I/II clinical trial for the treatment of non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. It is also developing TC-510, a mesothelin-targeted TRuC-T cell that has completed preclinical trials to treat solid tumors; and TC-520, a fratricide resistant CD70 targeting TRuC-T cell for the treatment of renal cell carcinoma. The company was formerly known as TCR2, Inc. and changed its name to TCR2 Therapeutics Inc. in November 2016. TCR2 Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
1.48 USD
0 (0%)
TCRR Financial Statements
Year
2022
2021
2020
2019
CF from Operating Activities
-101.46M
-81.6M
-56.74M
-41.36M
Net Income
-151.82M
-99.81M
-67.12M
-47.6M
Depreciation & Amortization
3.05M
2.83M
1.59M
862k
Deferred Income Taxes
-293k
99k
131k
0
Stock Based Compensation
11.38M
12.27M
8.49M
6.7M
Change in Working Capital
9.58M
1.62M
872k
-1.1M
Accounts Receivable
0
0
0
0
Inventory
0
0
0
0
Accounts Payable
1.17M
-771k
451k
-179k
Other Working Capital
8.41M
2.39M
421k
-920k
Other Non-Cash Items
26.65M
1.4M
-702k
-225k
CF from Investing Activities
-88.49M
78.45M
-48.94M
-20.41M
Investments in Property, Plant & Equipment
-15.45M
-11.45M
-7.16M
-3.88M
Net Acquisitions
15.45M
351k
7.78M
4.15M
Investment Purchases
-267.52M
-50.73M
-152.81M
-126.26M
Sales/Maturities of Investments
194.49M
140.62M
111.04M
109.72M
Other Investing Activites
-15.45M
-351k
-7.78M
-4.15M
CF from Financing Activities
125k
132.14M
134.7M
79.52M
Debt Repayment
0
0
0
0
Common Stock Issued
256k
131.33M
133.57M
79.13M
Common Stock Repurchased
0
0
0
0
Dividends Paid
0
0
0
0
Other Financing Activites
125k
132.14M
134.7M
79.52M
Free Cash Flow
-116.91M
-93.05M
-63.9M
-45.24M
Operating Cash Flow
-101.46M
-81.6M
-56.74M
-41.36M
Capital Expenditures
-15.45M
-11.45M
-7.16M
-3.88M
Cash at Beginning of Period
223.72M
94.74M
65.71M
47.96M
Cash at End of Period
33.9M
223.72M
94.74M
65.71M
Net Change In Cash
-189.82M
128.98M
29.02M
17.75M
Retained Earning Schedule
Year
2022
2021
2020
2019
Retained Earnings (Previous Year)
-349.52M
-249.72M
-182.59M
-85.59M
Net Income
-151.82M
-99.81M
-67.12M
-47.6M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-501.34M
-349.52M
-249.72M
-182.59M
Other Distributions
-151.82M
-99.81M
-67.12M
-97M
PPE Schedule
Year
2022
2021
2020
2019
Gross PPE
28.68M
45.36M
10.01M
4.93M
Annual Depreciation
63.88M
2.83M
1.59M
862k
Capital Expenditure
-15.45M
-11.45M
-7.16M
-3.88M
Net PPE
-19.75M
53.98M
15.59M
7.94M
Intangible and Goodwill Schedule
Year
2022
2021
2020
2019
Acquisitions and Adjustments
0
0
0
0
Goodwill (Previous Year)
0
0
0
0
Goodwill
0
0
0
0
All figures are in USD.
